Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 6

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Hepatol. Feb 28, 2016; 8(6): 331-339
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331

Table 4 Adverse events (≥ 20% in any treatment arm) n (%)

	Boceprevir plus PR (n = 159)	PR (n = 78)
Any AE	155 (97.5)	71 (91.0)
Neutropenia	84 (52.8)	31 (41.0)
Pyrexia	77 (48.4)	36 (46.2)
Anemia	75 (47.2)	19 (24.4)
Leukopenia	62 (39.0)	25 (32.1)
Dysgeusia	59 (37.1)	3 (3.8)
Asthenia	44 (27.7)	23 (29.5)
Headache	43 (27.0)	25 (32.1)
Influenza-like illness	39 (24.5)	14 (17.9)
Nausea	39 (24.5)	9 (11.5)
Anemia
8.5-10 g/dL	56 (35.2)	9 (11.5)
< 8.5 g/dL	10 (6.3)	2 (2.6)
Ribavirin dose reduction	65 (40.9)	14 (17.9)
EPO use	15 (9.4)	3 (3.8)
Serious AE	17 (10.7)	9 (11.5)
Discontinued because of an AE	7 (4.4)	2 (2.6)
Dose modification due to an AE	89 (56.0)	26 (33.3)

AE: Adverse event; EPO: Erythropoietin; PR: Peginterferon/ribavirin.

Citation: Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA, The P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339
URL: https://www.wjgnet.com/1948-5182/full/v8/i6/331.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i6.331

Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA, The P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339 [PMID: 26962399 DOI: 10.4254/wjh.v8.i6.331]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.